Catalio Capital Management, a multi-strategy life sciences investment firm, has closed its third venture fund, Catalio Nexus Fund III, with more than $381 million in total capital commitments.

Fund III will invest in biomedical technology companies at all stages of growth. The fund received significant backing from current Catalio investors and several new institutional investors, foundations and endowments. Catalio Capital Management is an investment firm that focuses on biomedical technology companies developing drugs, devices, diagnostics and data-driven insights.

Dr. Diamantis Xylas, Catalio’s head of research, said, ‘‘Our pipeline across the biotech and life sciences space is as robust as ever, and we look forward to continuing to back exceptional scientist-entrepreneurs and identify attractive investments that deliver treatment options to patients in need and drive returns for our investors.”